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Isocratic elutionAbstract Two chromatographic methods were developed and validated for the simultaneous
determination of Mometasone furoate (MO) and Formoterol fumarate dihydrate (FOR). Combi-
nation of MO and FOR is used for the treatment of asthma in patients suffering from reversible
obstructive airway disease. The ﬁrst chromatographic method was based on using aluminum
TLC plates pre-coated with silica gel GF254 as the stationary phase and chloroform:ethyl acetate:
methanol:toluene:formic acid (5:2:2:2:0.1, by volume) as the mobile phase followed by densitomet-
ric measurement of the separated bands at 233 nm. The second method is a high performance liquid
chromatographic method for the separation and determination of MO and FOR using reversed
phase C18 column with isocratic elution. The mobile phase composed of methanol: 0.5% ammo-
nium acetate pH adjusted with acetic acid (80:20, v/v) at a ﬂow rate of 1.0 mL/min. Quantitation
was achieved with UV detection at 220 nm. The speciﬁcity of the developed methods was investi-
gated by analyzing the pharmaceutical dosage form. The validity of the proposed methods was
assessed using the standard addition technique. The obtained results were statistically compared
with those obtained by the reported methods, showing no signiﬁcant difference with respect to accu-
racy and precision at p= 0.05.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Asthma is a chronic inﬂammatory disorder of the airways.
During asthma attacks, the smooth muscle cells in the bronchi
constrict, the airways become inﬂamed and swollen, andbreathing becomes difﬁcult.1 Therefore one of the ways of
treating it is a combination of inhaled corticosteroids to reduce
the inﬂammation of the airways and prevent the loss of lung
functions2 with long acting b2 agonists (LABA) which acts
locally on the lung as a bronchodilator and relaxes muscles
Figure 1 Structural formula of (a) Mometasone furoate MO and (b) Formoterol fumarate dihydrate FOR.
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combination is Mometasone furoate (MO), (9a,21-dichloro-1
1b,17-dihydroxy-16a-methylpregna-1,4-diene-17-yl furan-2-
carboxylate) (Fig. 1a) which acts as a corticosteroid and
Formoterol fumarate dihydrate (FOR), (N-[2-hydroxy-5-[(1RS)-
1-hydroxy-2-[[(1RS)-2-(4-methoxyphenyl)-1-methylethyl]amino]
ethyl]phenyl]formamide(E)-butenedioate dehydrate) (Fig. 1b)
which acts as a long acting b2 agonist.3
Literature survey reveals that MO and FOR are ofﬁcial
drugs in European Pharmacopoeia,4 also MO is ofﬁcial in Uni-
ted States Pharmacopoeia.5 Several analytical methods have
been reported for the determination of MO alone or in combi-
nations with other drugs including, spectrophotometry,4,6–9
TLC10,11 and HPLC.5,12–20 Besides, several methods have been
reported for the determination of FOR alone or in combina-
tions including, non aqueous titration,4 spectrophotome-
try,21–24 voltammetry,25 capillary electrophoresis,26 and
HPLC.18–20,27–32 The aim of this work is to develop simple
chromatographic methods for the simultaneous determination
of MO and FOR in pharmaceutical dosage form.2. Experimental
2.1. Instruments
The thin-layer chromatographic (TLC) system consisted of a
Camag Linomat autosampler (Muttenzl, Switzerland), a
Camag microsyringe (100 lL) and a Camag 35/N/30319 TLC
scanner with winCATS software; an ultraviolet (UV) lamp with
a short wavelength at 254 nm (Desaga, Wiesloch, Germany);
and TLC plates precoated with silica gel GF254 10  20 cm,
0.25 mm thickness (Merck, Darmstadt, Germany).
Shimadzu HPLC system consisted of a pumping system
(model LC-10 AD vp), an ultra-violet variable wavelength
detector (model SPD-10A vp), Degasser (model DGU-12A)
and System controller (model SCL-10A vp) Equipped with a
prominence autosampler (model SIL-20A) (Shimadzu, Kyoto,
Japan). An Inertsil ODS-3 column (5 lm, 250 mm  4.6 mm i.
d.) was used as stationary phase (GL Sciences, Tokyo, Japan).
2.2. Materials and reagents
2.2.1. Pure standard
Mometasone furoate was kindly supplied by SIGMA Pharma-
ceutical Industries, Cairo, Egypt, its purity was found to be
100.12 ± 0.762 according to the ofﬁcial method.5Formoterol fumarate dihydrate was kindly supplied by
NOVARTIS pharmaceuticals, Cairo, Egypt, its purity was
found to be 100.02 ± 0.592 according to the reported
method.19
2.2.2. Pharmaceutical dosage form
Dulera Inhalation aerosol (Batch No. GLG122) labeled to
contain 100 lg of MO and 5 lg of FOR per actuation, was
manufactured by (MERCK & CO. INC, White House Station,
USA) and obtained from the American market.
2.2.3. Chemicals and reagents
All chemicals used throughout the work were of analytical
grade and solvents for HPLC were of HPLC grade. These
included methanol (Sigma-Aldrich, Belgium), chloroform
(Sigma-Aldrich, Belgium) and double distilled deionized water
(Otsuka, Cairo, Egypt). Ethyl acetate, toluene, formic acid and
ammonium acetate were purchased from Al-Nasr Pharmaceu-
tical Chemicals Co., Cairo, Egypt.
2.2.4. Standard solutions
– Standard stock solution of MO: 1.0 mg/mL in methanol.
– Standard stock solution of FOR: 1.0 mg/mL in methanol.
2.2.5. Working Solutions
For TLC-spectrodensitometric method: Working solution of
FOR (200 lg/mL) was prepared from its stock solution using
methanol as a solvent.
For HPLC method: Working solutions of MO (400 lg/mL)
and FOR (100 lg/mL) were prepared from their respective
stock solutions using mobile phase as a solvent.
2.3. Procedures
2.3.1. Construction of the calibration curves
2.3.1.1. For TLC-spectrodensitometric method. Accuratelymea-
sured aliquots of MO stock standard solution (1 mg/mL) and
FOR working solution (200 lg/mL) were spotted onto TLC
plates using Camag Linomat autosampler with microsyringe
(100 lL). The plates were then developed by the ascending tech-
nique using chloroform:methanol:ethyl acetate:toluene:formic
acid (5:2:2:2:0.1, by volume) as a mobile phase. The plates were
then removed and air-dried. The chromatogram was scanned at
233 nm. Calibration curves representing the relationship
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tions of each of MO (2–14 lg/band) and FOR (0.1–5 lg/band)
were plotted.
2.3.1.2. For HPLC method. Aliquots equivalent to 100–
3000 lg of MO and 10–500 lg of FOR were accurately mea-
sured and transferred from their working solutions into a set
of 10-mL volumetric ﬂasks and the volumes were completed
to the mark with the mobile phase (methanol: 0.5% ammo-
nium acetate pH 5.7 (80:20; v/v)). A 20-lL aliquot of each
solution was injected into an Inertsil ODS-3 column (5 lm,
250 mm  4.6 mm i.d.), using the mobile phase, at ﬂow rate
1.0 mL/min and UV detection at 220 nm. Two calibration
curves were constructed by plotting the relative peak area,
using 100 lg/mL of MO and 25 lg/mL of FOR as the external
standards, against the corresponding concentrations of each
drug.
2.3.2. Application to pharmaceutical formulations
The actuator after shaking was inverted and placed in a beaker
containing 4 mL methanol, and then the beaker was covered
tightly. Ten actuations were delivered in the beaker, then the
actuator was washed with methanol. The solution was trans-
ferred accurately into 10-mL volumetric ﬂask and the volume
was completed with methanol to prepare dosage form solution
containing 100 lg/mL MO and 5 lg/mL FOR. For TLC-
spectrodensitometric determination of both drugs, 40 lL was
applied onto TLC plates.
For HPLC analysis, dosage form solution was prepared as
mentioned above but completing the volume with the mobile
phase instead of completing with methanol and then injected
to the column. The procedure was completed as mentionedFigure 2 TLC chromatogram of a resolved mixture conunder construction of calibration curves for each method.
The concentration of MO and FOR was calculated from the
corresponding regression equations.3. Results
Several trials were conducted to develop the optimum chromato-
graphic conditions for the sufﬁcient separation of both drugs
including chloroform:methanol (2:8, v/v), methanol:toluene
(8:2, v/v) and chloroform:ethyl acetate:toluene (5:4:3, by
volume) but bad resolution was obtained. The results of the
TLC system were satisfactory when using chloroform:ethyl a
cetate:methanol:toluene:formic acid (5:2:2:2:0.1, by volume)
as the mobile phase. Rf values were found to be 0.81 ± 0.02
and 0.17 ± 0.02 for MO and FOR, respectively as shown in
(Fig. 2). This separation allows the determination of MO
and FOR at 233 nm without any interference from each other.
HPLC method was also tried to separate MO and FOR,
therefore several trials have been undertaken to reach the opti-
mum stationary/mobile phases matching. Good chromato-
graphic separation of the two drugs in their binary mixtures
could be achieved using an Inertsil ODS-3 column (5 lm,
250 mm  4.6 mm i.d.), with a mobile phase consisting of
(methanol: 0.5% ammonium acetate (80:20, v/v) pH 5.7
adjusted by glacial acetic acid) at ﬂow rate 1.0 mL/min, fol-
lowed by UV detection at 220 nm, (Fig. 3). Calibration curves
were plotted for both TLC and HPLC for the determination of
the cited drugs.
An overall system suitability testing was calculated (Table 1)
to determine whether the operating system performed
properly.taining 0.5 lg/band of FOR and 10 lg/band of MO.
Figure 3 HPLC chromatogram of resolved mixture containing 15 lg/mL of FOR and 300 lg/mL of MO.
Table 1 Parameters required for system suitability test of TLC-densitometric and HPLC methods.
Parameter TLC HPLC Reference values (5)
MO FOR MO FOR
Retention time (tR) [min] 6.925 2.717
Retardation factor (Rf) 0.81 0.17
Tailing factor (T) 0.89 1.2 1 1 T= 1, for a typical symmetrical peak
Capacity factor (K0) 7.343 2.273 1 < K0 < 10
Selectivity factor (a) 4.76 3.23 a> 1
Resolution factor (Rs) 12.8 12.27 Rs> 2
Column eﬃciency (N) 3503 2485 N> 2000
HETPa [mm] 0.071 0.100
HETPa = height equivalent to theoretical plates (length of column in mm/N).
102 H.A. Merey et al.The proposed methods were validated according to Inter-
national Conference on Harmonization (ICH) guidelines
(Table 2). The table also shows the assay parameters of the
regression equations and the ranges of concentration.
The proposed methods were successfully applied for the
determination of MO and FOR in Dulera inhaler.
The results shown in Table 3 were satisfactory. The
validity of the proposed methods was assessed by applyingthe standard addition technique, no interference due to
excipients was observed as shown from the results in
Table 3.
The results obtained by applying the proposed methods for
the analysis of pure MO and FOR compared to those obtained
by applying the ofﬁcial5 and reported methods,19 respectively,
they showed no signiﬁcant difference regarding accuracy and
precision Table 4.
Table 2 Assay validation sheet of the proposed methods for the simultaneous determination of Mometasone furoate (MO) and
Formoterol fumarate dihydrate (FOR).
Parameter TLC HPLC
MO FOR MO FOR
Range 2–14 lg/band 0.1–5 lg/band 10–300 lg/mL 1–50 lg/mL
Linearity
Slope Slope 1 = 0.1286
Slope 2 = 3.6519
Slope 1 = 0.3501
Slope 2 = 4.5039
0.0083 0.04
Intercept 3.0026 0.2202 0.1688 0.008
SE of intercept 1.7826 0.3482 0.0048 0.0005
Correlation coeﬃcient (r) 0.9999 1 0.9999 1
Accuracy
(mean ± SD)
100.10 ± 1.039 99.96 ± 0.970 100.24 ± 0.494 100.24 ± 0.819
Precision
Intradaya 0.970 0.870 0.664 0.735
Interdayb 1.269 0.879 0.753 0.916
LOD 0.26 lg/band 0.01 lg/band 2.52 lg/mL 0.06 lg/mL
LOQ 0.78 lg/band 0.04 lg/band 7.63 lg/mL 0.18 lg/mL
Robustnessc 0.881 0.933 0.845 0.966
a The intraday RSD% for TLC RSD% of three concentrations (3, 7 and 11 lg/band) of MO and (0.26, 0.46 and 0.66 lg/band) of FOR
repeated three times within the day. For HPLC RSD% of three concentrations (20, 70 and 140 lg/mL) of MO and (2.5, 10 and 20 lg/mL) of
FOR repeated three times within the day.
b The inter-day RSD% for TLC RSD% of three concentrations (3, 7 and 11 lg/band) of MO and (0.26, 0.46 and 0.66 lg/band) of FOR
repeated three successive days. For HPLC RSD% of three concentrations (20, 70 and 140 lg/mL) of MO and (2.5, 10 and 20 lg/mL) of FOR
repeated three successive days.
c For TLC, RSD% of three concentrations (3, 7 and 11 lg/band) of MO and (0.26, 0.46 and 0.66 lg/band) of FOR) using 0.2 mL of formic
acid instead of 0.1 mL. For HPLC, RSD% of three concentrations (20, 70 and 140 lg/mL) of MO and (2.5, 10 and 20 lg/mL) of FOR at ﬂow
rate 1.2 mL/min instead of 1 mL/min.
Table 3 Determination of Mometasone furoate (MO) and Formoterol fumarate dihydrate (FOR) in their Dosage form and
application of standard addition technique using the proposed methods.
Product Method Drug Recovery%* ± RSD Standard addition
Claimed amount taken Added** Found** Recovery%*
Dulera inhalation aresol
(Batch No. GLG122)
TLC MO 99.60 ± 0.351 4 lg/band 2 2.01 100.50
4 3.99 99.75
6 5.97 99.50
Mean ± RSD 99.91 ± 0.521
FOR 101.00 ± 0.910 0.2 lg/band 0.1 0.100 100.00
0.2 0.201 100.50
0.3 0.299 99.67
Mean ± RSD 100.06 ± 0.418
HPLC MO 100.83 ± 0.630 100 lg/mL 60 61.16 101.93
100 102.98 102.98
120 122.13 101.78
Mean ± RSD 102.23 ± 0.639
FOR 101.16 ± 0.436 5 lg/mL 3 3.06 102.00
5 5.00 100.00
7 7.11 101.57
Mean ± RSD 100.17 ± 1.050
* Average of three determinations of dosage form.
** Added and found concentrations were lg/band in case of TLC method and lg/mL in case of HPLC method.
Determination of Mometasone furoate and Formoterol fumarate dihydrate 1034. DiscussionPlanar chromatography with precise application of the sam-
ples and computer controlled evaluation and quantiﬁcation
of the developed chromatograms has been considered to be a
reliable technique for purity control and for quantitative drug
testing.33 Therefore the aim of this work is to develop simple,accurate, rapid, speciﬁc and valid spectro-densitometric
method. This separation allows the determination of MO
and FOR without any interference from each other. A polyno-
mial relationship was found to exist between the integrated
peak area of the separated spots at the selected wavelength
(233 nm) and the corresponding concentrations of MO and
FOR in the range of 2–14 lg/band and 0.1–5 lg/band for
MO and FOR, respectively.
Table 4 Statistical comparison of the results obtained by the proposed methods and the reported methods for the analysis of
Mometasone furoate (MO) and Formoterol fumarate dihydrate (FOR).
Parameter TLC HPLC Reported methods
MO FOR MO FOR MO (5)b FOR (19)c
Mean 100.10 99.96 100.24 100.24 100.12 100.02
SD 1.039 0.969 0.494 0.819 0.762 0.592
Variance 1.060 0.939 0.244 0.670 0.581 0.350

















a The ﬁgures in parenthesis are the corresponding theoretical values at p= 0.05.
b Ofﬁcial method is HPLC for MO determination using C8 column (5 lm, 4.6  250 mm), methanol:water (65:35, v/v) as a mobile phase at a
ﬂow rate of 1.7 mL/min and UV detection at 254 nm.
c HPLC method for FOR determination using C18 column (5 lm, 4.6  150 mm), sodium dihydrogen phosphate buffer:acetonitrile (50:50,
v:v) as a mobile phase. pH = 3 adjusted by diluted ortho-phosphoric acid at a ﬂow rate of 1 mL/min and UV detection at 220 nm.
104 H.A. Merey et al.The regression equations were computed for MO and
found to be:
A ¼ 0:1286X2 þ 3:6519Xþ 3:0026 r ¼ 0:9999 for MO
A ¼ 0:3051X2 þ 4:5039Xþ 0:2202 r ¼ 1 for FOR
where A is the integrated peak area multiplied by (103), X is
the corresponding concentration in lg/band and r is the corre-
lation coefﬁcient.
The suggested chromatographic system for the HPLC
method allows complete base line separation at reasonable
time. The linearity of the detector’s response of the studied
drugs was determined by plotting a relative peak area (calcu-
lated following the external standard technique using 100 lg/
mL of MO and 25 lg/mL of FOR as the external standards
for MO and FOR, respectively) versus concentrations and lin-
ear correlation was obtained. The regression equations were
computed for MO and FOR and found to be:
A ¼ 0:0083Cþ 0:1688 r ¼ 0:9999 for MO
A ¼ 0:04Cþ 0:0011 r ¼ 1 for FOR
where A is the relative peak area, C is the corresponding con-
centration in lg/mL and r is the correlation coefﬁcient.
By comparing the developed HPLC method with the
reported methods18–19 we found that, the developed method
is more sensitive and liner over a wider range of concentration
1–50 lg/mL for FOR and 10–300 lg/mL for MO than that of
the reported method18 3–9 lg/mL for FOR and 100–300 lg/
mL for MO. Also the developed HPLC method shows a
shorter retention time, where FOR and MO eluted after
2.7 min. and 6.9 min., while eluted after 3.4 min. and
9.2 min., respectively in the reported method.19
4.1. Method validation
The proposed methods were validated according to the ICH
Q2 (R1) recommendations.34 The method was validated for
parameters such as system suitability, linearity, limit of detec-
tion (LOD), limit of quantitation (LOQ), accuracy, precision
and selectivity.4.1.1. System suitability
The system suitability test is an integral part of chromato-
graphic method development and it is used to verify that the
system is adequate for the analysis to be performed; the system
suitability parameters for MO and FOR were evaluated. The
suitability of the chromatographic system was determined
according to USP guidelines and with acceptance of the
obtained parameter values.5
4.1.2. Linearity and ranges
Under the above mentioned experimental conditions, linear
relationships were obtained by plotting the drug concentra-
tions either against relative peak areas or integrated peak areas
for each drug, for HPLC and TLC methods, respectively.
4.1.3. Accuracy
The accuracy of the proposed methods was validated by ana-
lyzing pure samples of each MO, FOR in triplicate. The con-
centrations of the active drugs were calculated from the
corresponding regression equations.
4.1.4. Precision
It was evaluated by calculating intra and inter-day precisions.
By repeating the assay of three different concentrations of each
of the cited drugs three times in the same day and assaying the
same samples in triplicate on three successive days using the
developed chromatographic methods and calculating the
recovery% and RSD%.
4.1.5. Specificity
The speciﬁcity of the developed methods was investigated by
analyzing the pharmaceutical dosage form. The spots of the
active drugs in the dosage form were conﬁrmed by comparing
their Rf values and densito-spectra of the spot with that of a
standard drugs solutions (in TLC method).
4.1.6. Robustness
It was evaluated by calculating the RSD% of three different
concentrations of each of the cited drugs after making a
deliberate change in the assay conditions of both TLC and
HPLC.
Determination of Mometasone furoate and Formoterol fumarate dihydrate 1055. Conclusion
The suggested chromatographic methods provide simple, sen-
sitive, accurate and reproducible methods for quantitative
analysis of MO and FOR in their binary mixtures and pharma-
ceutical dosage form. The developed TLC method is highly
sensitive. It has the advantages of short run time, large sample
capacity and use of minimal volume of solvents. HPLC
method gives a good resolution between the proposed compo-
nents within suitable analysis time; it is highly speciﬁc but
more expensive. The proposed methods have advantage than
other published methods of being more sensitive, simple, lower
time consuming and easy in application on inhaler dosage
form.
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